COA ↓

Product

COA Doc

SYN-2614

99.3% Purity SYN-2614 Research Grade HPLC Verified

Semax

ACTH(4-10) Heptapeptide · Research Grade

Select Strength — 10mg

$105.00

C₃₇H₅₁N₉O₁₀S MW: 813.92 g/mol CAS: 80714-61-0

In Stock — Same Day Dispatch on Orders Before 2PM AEST Mon–Fri

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch

99.3%

HPLC Purity

Lot Number SYN-2614-SEMAX

Test Date March 2026

Labeled 10 mg

Actual 10.01 mg

99.6%

HPLC Purity

Lot Number SYN-2513-SEMAX

Test Date January 2026

Labeled 10 mg

Actual 10.02 mg

Research Data

KEY FINDINGS

🧬

8–12×

BDNF Elevation in Hippocampus

Within 24h of administration — Dolotov SN et al., 2006

🔬

Phase II

Ischaemic Stroke Clinical Trial

Significant cognitive recovery vs. placebo at 30 days

✅

99.3%

HPLC-Verified Purity

Current batch SYN-2614, third-party accredited lab

❄️

24mo

Lyophilised Shelf Life

At −20°C sealed under inert atmosphere

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

🧠 BDNF Induction

8–12× Hippocampal BDNF — 24-Hour Response

Dolotov et al. characterised Semax-induced BDNF and NGF upregulation in hippocampal tissue, demonstrating the fastest and largest BDNF elevation of any synthetic peptide studied — with both transcription-level mRNA increases and protein-level confirmation.

🔬 10.5× hippocampal BDNF elevation within 24h — the most rapid neurotrophin induction documented for any synthetic peptide.

PMID 16466406 — J. Neurochem.

🔬 Stroke Recovery

Phase II Ischaemic Stroke Clinical Data

Russian Phase II trials in acute ischaemic stroke patients demonstrated significant improvement in cognitive recovery scores at 30 days vs. placebo, establishing Semax as a registered neuroprotective agent. The ACTH(4-10) core provides VEGF and VEGFR2 upregulation supporting neovascularisation.

🔬 Approved in Russia for ischaemic stroke recovery since 1982 — Phase II clinical data supporting neuroprotection.

PMID 16466406 — J. Neurochem.

8 –12×

Hippocampal BDNF Elevation Within 24 Hours

Semax (ACTH 4-10 heptapeptide analogue) produces 8–12× BDNF elevation in hippocampal tissue within 24 hours — the most rapid neurotrophin induction documented for any synthetic peptide in cell culture and rodent CNS models.

BDNF Elevation — Semax vs. Control

Semax (BDNF at 24h) 10.5×

NGF induction 4.2×

Baseline 1.0×

Source: Dolotov SN et al., J. Neurochem., 2006

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2614-SEMAX

Specification	Value
CAS Number	80714-61-0
Molecular Formula	C₃₇H₅₁N₉O₁₀S
Molecular Weight	813.92 g/mol
Purity (HPLC)	99.3%
Appearance	White lyophilised powder
Solubility	Soluble in water (1 mg/mL)
Storage	−20°C long-term / 2–8°C short-term
Shelf Life	24 months from production date
Research Grade	Yes — For In Vitro Use Only

10.5 ×

BDNF Elevation in Hippocampal Cultures at 24h vs. Baseline

Semax 10.5×

NGF induction 4.2×

Baseline 1.0×

Comparative Activity Profile

Semax Selank

Observed Adverse Indicators

Cytotoxicity in vitro

None

BDNF receptor downregulation

None

Neurotoxicity at research doses

None

Transient nasal irritation

Minimal

⚠️ Theoretical Concern

Intranasal Delivery — Concentration-Dependent CNS Effects

Semax is designed for intranasal delivery with nose-to-brain transport. In vitro cell culture studies use aqueous solution. Researchers should account for rapid BDNF/NGF axis activation when designing hippocampal or CNS-focused experiments.

Clinically approved in Russia since 1982 — extensive safety data from ischaemic stroke populations
No TrkB (BDNF receptor) downregulation in published in vitro and rodent studies at effective doses
No cytotoxicity, genotoxicity, or neurotoxicity in published laboratory models at research concentrations

Semax

BATCH VERIFICATION

KEY FINDINGS

IN VITRO RESEARCH OVERVIEW

8–12× Hippocampal BDNF — 24-Hour Response

Phase II Ischaemic Stroke Clinical Data

PURITY VERIFICATION

TRIAL RESULTS

SAFETY PROFILE

Intranasal Delivery — Concentration-Dependent CNS Effects

FREQUENTLY ASKED QUESTIONS

RESEARCH CITATIONS